Pertuzumab(CAS: 380610-27-5)

Pertuzumab (CAS: 380610-27-5) is a glycoprotein therapeutic monoclonal antibody with a molecular weight of approximately 144 kDa. It is soluble in water and has a crystalline form that is stable under normal storage conditions. Pertuzumab is highly reactive with certain cell surface receptors, making it effective in inhibiting HER2 signaling pathways in cancer treatment.

Pertuzumab (CAS: 380610-27-5) is synthesized through recombinant DNA technology using mammalian cell cultures, such as Chinese hamster ovary (CHO) cells. The process involves gene cloning, cell transfection, and cell culture expansion. High yields and selectivity are achieved using optimized culture conditions and process controls.

Pertuzumab (CAS: 380610-27-5) is primarily used in the pharmaceutical industry for cancer treatment, specifically in combination with other therapies to target HER2-positive breast and gastric cancers. It is also utilized in the biotechnology sector for research and development of new cancer treatments.

When handling Pertuzumab (CAS: 380610-27-5), laboratory personnel should use personal protective equipment (PPE) such as gloves, masks, and appropriate lab coats. It should be stored refrigerated at 2-8°C and protected from light. Spills should be handled with care according to safety data sheets (SDS) guidelines. Fume hoods should be used during administration to minimize inhalation risk.